Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients

Status Not yet recruiting

Clinical Trial Summary

The percentages of participants in clinical studies haven't always been perfectly representative of a particular group. This research examines the variables that affect a patient's choice to enroll in, discontinue participation in, or resume participation in a clinical trial for hairy cell leukemia. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of hairy cell leukemia studies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05859932
Study type	Observational
Source	Power Life Sciences Inc.
Contact	Michael B Gill
Phone	415-900-4227
Email	bask@withpower.com
Status	Not yet recruiting
Phase
Start date	June 2024
Completion date	June 2026

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05645744` - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Active, not recruiting	`NCT03805932` - Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia	Phase 1
Recruiting	`NCT04324112` - Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL	Phase 2
Active, not recruiting	`NCT01711632` - BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia	Phase 2
Withdrawn	`NCT03739606` - Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer	Phase 2
Active, not recruiting	`NCT00923013` - Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia	Phase 2
Completed	`NCT00898079` - Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Completed	`NCT01720758` - Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease	N/A
Recruiting	`NCT04815356` - Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant	Phase 1
Recruiting	`NCT02131753` - Therapy Optimisation for the Treatment of Hairy Cell Leukemia	Phase 2/Phase 3
Completed	`NCT00321555` - LMB-2 to Treat Hairy Cell Leukemia	Phase 2
Completed	`NCT00586924` - A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia	Phase 1
Recruiting	`NCT06340737` - AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas	Phase 1
Recruiting	`NCT05388123` - Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia	Phase 2
Recruiting	`NCT04952974` - B-cell Chronic Lymphoid Malignancies Markers
Recruiting	`NCT00412594` - Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia	Phase 2
Recruiting	`NCT04775745` - Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.	Phase 1
Completed	`NCT03010358` - Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT01059786` - Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia	Phase 2
Recruiting	`NCT04322383` - Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	Phase 2